Medtrace Pharma A/S operates a platform for the production, infusion and analysis of 15O-water used in medical imaging. The technology is applied to myocardial perfusion imaging and other indications that require perfusion data, including heart scans. The company raised $30 million in a Series B to scale its platform and operations. Lead investors in the round are Swisscanto Invest, ATP and the Bankinvest group. CEO and co‑founder Martin Stenfeldt said the funding will enable ramping European and U.S. expansion plans in myocardial perfusion imaging and other perfusion applications. The capital is intended to support production, infusion and analytical capabilities needed to deploy 15O-water imaging more broadly across clinical settings.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2024